PharmaCyte Biotech, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from PharmaCyte Biotech, Inc.'s yearly results (2023–2026), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Tangible Net Worth Ratio: Of every $100 of net worth, $100 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than almost all Healthcare companies in United States.
- Tangible Assets Ratio: Of every $100 the company owns, $100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 98% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
100%Of every $100 the company owns, $100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 98% of Healthcare companies in United States.
Tangible Net Worth Ratio
100%Of every $100 of net worth, $100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than almost all Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (9)
PharmaCyte Biotech, Inc. made a loss over the last year. PharmaCyte Biotech, Inc. owes $0.19 for every $1 it owns. PharmaCyte Biotech, Inc. made a loss in the year to Apr 2026, after a profit the year before.
Compared with Healthcare companies in United States · latest annual results Apr 2026.
P/E ratio
LossPharmaCyte Biotech, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.13The share price is 0.13 times PharmaCyte Biotech, Inc.'s book value per share, lower than almost all Healthcare companies in United States.
Market cap
$4 MThe total market value of all of PharmaCyte Biotech, Inc.'s shares at today's price (share price × number of shares), smaller than 95% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$30 MWhat PharmaCyte Biotech, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Jul 2026).
Book value per share
$2.78Net worth divided by the number of shares. The share price of $0.35 is 0.1 times this, which is the P/B above.
Return on equity (ROE)
-44.0%PharmaCyte Biotech, Inc. lost 44.0% of its shareholders' money over the last year, higher than 53% of Healthcare companies in United States.
Owes vs Owns
0.19×PharmaCyte Biotech, Inc. owes $0.19 for every $1 it owns (low), lower than 74% of Healthcare companies in United States.
Dividend yield
NonePharmaCyte Biotech, Inc. does not currently pay a dividend.
Profit growth
LossPharmaCyte Biotech, Inc. made a loss in the year to Apr 2026, after a profit the year before.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For PharmaCyte Biotech, Inc.: $4 M ÷ $30 M (31 Jul 2026) = 0.1.
What is PharmaCyte Biotech, Inc.'s return on equity?
PharmaCyte Biotech, Inc. lost 44.0% of its shareholders' money over the last year, higher than 53% of Healthcare companies in United States.
How much does PharmaCyte Biotech, Inc. owe compared with what it owns?
PharmaCyte Biotech, Inc. owes $0.19 for every $1 it owns (low), lower than 74% of Healthcare companies in United States.
Does PharmaCyte Biotech, Inc. pay a dividend?
No. PharmaCyte Biotech, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.